[{"orgOrder":0,"company":"Certara","sponsor":"Galderma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Certara Partners with Galderma in Advancing Modeling and Simulation Technology to Attain FDA Approval of AKLIEF\u00ae Topical Acne Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Partnership","leadProduct":"Trifarotene","moa":"RAR-gamma","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Certara","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Certara \/ Galderma","highestDevelopmentStatusID":"12","companyTruncated":"Certara \/ Galderma"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Almirall and WuXi Biologics sign strategic collaboration agreement for multiple bispecific antibodies targeting dermatology diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"CHINA","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Bispecific antibody","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"WuXi Biologics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"WuXi Biologics \/ Almirall, S.A","highestDevelopmentStatusID":"1","companyTruncated":"WuXi Biologics \/ Almirall, S.A"},{"orgOrder":0,"company":"23andMe","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Almirall signs a strategic agreement with 23andMe to license rights of a bispecific monoclonal antibody that blocks all three isoforms of IL-36 cytokine","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Collaboration","leadProduct":"Bispecific Monoclonal Antibody","moa":"IL-36","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"23andMe","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"23andMe \/ Almirall, S.A","highestDevelopmentStatusID":"4","companyTruncated":"23andMe \/ Almirall, S.A"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Lilly Announces Agreement to Acquire Dermira","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Acquisition","leadProduct":"Lebrikizumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":1.1000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":1.1000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Eli Lilly and Company","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly and Company"},{"orgOrder":0,"company":"George Washington University","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Exercises Patent Licensing Option with the George Washington University to Further Develop a Therapeutic for Cancer Patients Suffering Cutaneous Changes Like Rash and Hair Loss, as Well as Other Neurogenic Inflammation Side Effects","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Aprepitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"George Washington University","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"","sponsorNew":"George Washington University \/ Hoth Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"George Washington University \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Japan Tobacco","pharmaFlowCategory":"D","amount":"$113.0 million","upfrontCash":"$60.0 million","newsHeadline":"Dermavant Enters into Exclusive License Agreement with JT for Development and Commercialization of Tapinarof in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0.11,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.11,"dosageForm":"Topical Cream","sponsorNew":"Dermavant Sciences \/ Japan Tobacco","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant Sciences \/ Japan Tobacco"},{"orgOrder":0,"company":"Torii Pharmaceutical","sponsor":"Japan Tobacco Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JT to market CORECTIM in Japan to treat atopic dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Delgocitinib","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Torii Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Torii Pharmaceutical \/ Japan Tobacco Inc","highestDevelopmentStatusID":"10","companyTruncated":"Torii Pharmaceutical \/ Japan Tobacco Inc"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sol-Gel Announces Initiation of SGT-210 Phase 1 Proof of Concept Study in Palmoplantar Keratoderma (PPK)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"SGT-210","moa":"EGFR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Sol-Gel Technologies","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Sol-Gel Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sol-Gel Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Suzhou Connect Biopharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Connect Biopharma Reports Positive Topline Data from Moderate-to-severe Atopic Dermatitis (AD) Phase 1b Study of CBP-201 \\nD","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"CBP-201","moa":"IL-4 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Suzhou Connect Biopharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Suzhou Connect Biopharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Suzhou Connect Biopharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bayer and Azitra Partner to Harness the Human Skin Microbiome as a Source for New Natural Skin Care Products for Sensitive and Eczema-Prone Skin","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"GERMANY","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Staphylococcus epidermidis strain","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Bayer AG","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Bayer AG \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Bayer AG \/ Not Applicable"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Bio\u2019s Development Partner, Kaken Pharmaceutical, Submits New Drug Application for Sofpironium Bromide in Japan for Primary Axillary Hyperhidrosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Evelo Provides Update on Recent Positive EDP1815 Regulatory Interactions on Phase 2 Trial Design Resulting in Shorter Development Timeline to Registration","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"EDP1815","moa":"Th17\/Th2\/Th1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Evelo Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Evelo Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Head-to-Head Phase 3 Data Show SKYRIZI\u2122 (risankizumab) Superior to Cosentyx\u00ae (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Risankizumab","moa":"IL-23 alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"AbbVie Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AbbVie Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"AbbVie Inc \/ Not Applicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Completes Animal Safety Study of Proprietary BioLexa Platform for the Treatment of Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Antimicrobial therapy","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sirona Biochem: 100% Safety in Final Tox Study for Increased Concentration of TFC-1067","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"TFC-1067","moa":"Tyrosinase activity","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Sirona Biochem Corp","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sirona Biochem Corp \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Sirona Biochem Corp \/ Not Applicable"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipidor Announces Positive Topline Results of AKP01 Phase III Clinical Study Using Calcipotriol Spray Against Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"SWEDEN","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Not Applicable"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crescita Awarded Cannabis Research License from Health Canada","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Cannabinoid-based Product","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Crescita Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Crescita Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"Crescita Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Evolus","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Results from Phase III, Split-Face, Head-to-Head Study Comparing OnabotulinumtoxinA and PrabotulinumtoxinA in the Treatment of Crow\u2019s Feet Lines Published in Dermatologic Surgery","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Prabotulinumtoxin A","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Evolus","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Evolus \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evolus \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Announces Federal Circuit Granted its Motion to Vacate and Remand PTAB Decision Involving CTP-543","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte\\'s skin disease drug meets main goal in late-stage study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$1,100.0 million","newsHeadline":"Lilly Completes Acquisition of Dermira","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Acquisition","leadProduct":"Lebrikizumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":1.1000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":1.1000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Eli Lilly and Company","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Eli Lilly and Company"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"Undisclosed","newsHeadline":"Corbus Pharma Announces Proposed Public Offering of Common Stock","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Public Offering","leadProduct":"Lenabasum","moa":"CB2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0.040000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.040000000000000001,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Forte Biosciences","sponsor":"","pharmaFlowCategory":"D","amount":"$25.0 million","upfrontCash":"Undisclosed","newsHeadline":"Tocagen and Forte Biosciences Announce Merger","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Merger","leadProduct":"FB-401","moa":"TLR5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Forte Biosciences","amount2":0.029999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Topical","sponsorNew":"Forte Biosciences \/ ","highestDevelopmentStatusID":"8","companyTruncated":"Forte Biosciences \/ "},{"orgOrder":0,"company":"Bodor Laboratories","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"D","amount":"$3.5 million","upfrontCash":"$1.0 million","newsHeadline":"Brickell Biotech Announces Settlement of Dispute with Bodor Labs","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Bodor Laboratories","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Bodor Laboratories \/ Brickell Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Bodor Laboratories \/ Brickell Biotech"},{"orgOrder":0,"company":"Paratek Pharmaceuticals","sponsor":"Almirall","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Paratek Announces License Grant to Almirall for SEYSARA\u00ae (sarecycline) for Greater China Region","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Sarecycline","moa":"Bacterial protein synthesis","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Paratek Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Paratek Pharmaceuticals \/ Almirall","highestDevelopmentStatusID":"12","companyTruncated":"Paratek Pharmaceuticals \/ Almirall"},{"orgOrder":0,"company":"Foamix Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foamix Announces Publication of Phase 3 Studies Evaluating FMX103","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Foamix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Foamix Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Foamix Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revance Gest U.S. FDA Acceptance of BLA for DAXI","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Daxibotulinumtoxin A","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Revance Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Revance Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Crescita Reports Topline Results from Two Pivotal Clinical Studies","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"CTX-101","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Crescita Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Crescita Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Crescita Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PRIVIGEN Granted Orphan-Drug Designation","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Human Rho D Immune Globulin","moa":"IgG","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"CSL Behring","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL Behring \/ Not Applicable"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sol-Gel Announces Positive Topline Results from Open-Label, Long-Term Safety Study of Epsolay\u00ae for Treatment up to 52 Weeks","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Benzoyl Peroxide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Sol-Gel Technologies","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sol-Gel Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Aurigene","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurigene announces dose administration in first patient study for phase II study of psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"AUR101","moa":"RAR-gamma","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Aurigene","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurigene \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Aurigene \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces Positive Topline Results From Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream for Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Announces Results from Phase 2 Study of Investigational Therapy Nemolizumab for Moderate to Severe Prurigo Nodularis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Nemolizumab","moa":"IL-31 alpha receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Biotech Announces Publication of its U.S. Phase 2b Study Results for Sofpironium Bromide","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Tradipitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Vanda Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Vanda Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"InflaRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"InflaRx Announces Positive Initial Data from Ongoing Phase IIa Open Label Study with IFX-1 in Pyoderma Gangraenosum","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"GERMANY","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2020","year":"2020","type":"Not Applicable","leadProduct":"Ifx-1","moa":"Complement 5a receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"InflaRx","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"InflaRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"InflaRx \/ Not Applicable"},{"orgOrder":0,"company":"Foamix Pharmaceuticals","sponsor":"Menlo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Merger","leadProduct":"Serlopitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Foamix Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Foamix Pharmaceuticals \/ Menlo Therapeutics ","highestDevelopmentStatusID":"10","companyTruncated":"Foamix Pharmaceuticals \/ Menlo Therapeutics "},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite is Filing Drug Safety Update Report Showing Positive Safety Results ","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Can-Fite BioPharma \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Not Applicable "},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Roflumilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable "},{"orgOrder":0,"company":"Emerald Health Pharmaceuticals","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emerald Health Pharmaceuticals Receives Fast Track Designation from US FDA for EHP-101 in the Treatment of Systemic Sclerosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"EHP-101","moa":"PPAR gamma","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Emerald Health Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emerald Health Pharmaceuticals \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Emerald Health Pharmaceuticals \/ Not Applicable "},{"orgOrder":0,"company":"Fresh Tracks Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Brickell Biotech Announces Late-Breaking Oral Presentation at 2020 American Academy of Dermatology Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Fresh Tracks Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Fresh Tracks Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Fresh Tracks Therapeutics \/ Not Applicable "},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asana BioSciences Announce ASN008 Achieves Positive Results","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"ASN008","moa":"NaV Channel","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Asana BioSciences \/ Not Applicable ","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioSciences \/ Not Applicable "},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable ","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Not Applicable "},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Announces Positive Preclinical Data of WEG232 Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"WEG232","moa":"Substance P receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"Hoth Therapeutics \/ Not Applicable ","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Not Applicable "},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Pfizer\u2019s Dupixent rival makes the grade in phase 3\u2014again","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Abrocitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Discloses Acne Pre-clinical Data Planned for 2020 AAD Annual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"BX001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"BiomX","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"BiomX \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BiomX \/ Not Applicable"},{"orgOrder":0,"company":"Isoprene Pharmaceuticals","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","amount":"$0.1 million","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Enters into Letter of Intent with Isoprene Pharmaceuticals","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Retinamide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Isoprene Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Isoprene Pharmaceuticals \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Isoprene Pharmaceuticals \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Data from Phase 3 TRuE-AD Trials of Ruxolitinib Cream in Atopic Dermatitis to be Presented","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medimetriks Announces that Otsuka Achieved Positive Top-Line Phase 3 Results for MM36","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"JAPAN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Difamilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Otsuka Pharmaceutical","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Otsuka Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Otsuka Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"Piclidenoson","moa":"A3AR","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Can-Fite BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Can-Fite BioPharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Can-Fite BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Processa Pharmaceuticals To Move Forward With A PCS499 Phase 3 Trial After A Successful FDA Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","year":"2020","type":"Not Applicable","leadProduct":"PCS499","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Processa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Processa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Fillmed Laboratories","sponsor":"Crescita Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Crescita Signs Exclusive Distribution Agreement with FILLMED","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"January 2020","year":"2020","type":"Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunits","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Fillmed Laboratories","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fillmed Laboratories \/ Crescita Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Fillmed Laboratories \/ Crescita Therapeutics"},{"orgOrder":0,"company":"Curzion Pharmaceuticals","sponsor":"Horizon Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$45.0 million","newsHeadline":"Horizon Therapeutics Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Acquisition","leadProduct":"HZN-825","moa":"LyLPAR1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Curzion Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Curzion Pharmaceuticals \/ Horizon Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Curzion Pharmaceuticals \/ Horizon Therapeutics"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Concert Pharmaceuticals Announces Plans for CTP-543 Phase 3 Trials in Alopecia Areata","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Deuterated Ruxolitinib","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Concert Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Concert Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Concert Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Completes Patient Enrollment for Two Phase 3 Clinical Trials of Tapinarof for the Treatment of Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dermavant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menlo Therapeutics Announces Results from Two Phase 3 Clinical Trials of Serlopitant ","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Serlopitant","moa":"NK1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Menlo Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Menlo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Menlo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Announces Investigational New Drug Application Amendment for HST 001","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"HST 001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Not Applicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Commences Next Phase of VNLG-152 Study","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Retinamide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"ASLAN Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ASLAN Pharmaceuticals Temporarily Pauses Recruitment of New Patients Into ASLAN004 Study Due to COVID-19","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"SINGAPORE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ASLAN004","moa":"IL-13 alpha-1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"ASLAN Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ASLAN Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"ASLAN Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Sol-Gel Technologies","sponsor":"M. Arkin Dermatology Ltd","pharmaFlowCategory":"D","amount":"$28.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sol-Gel Technologies Announces Closing of Additional $5.0 Million Investment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Financing","leadProduct":"Benzoyl Peroxide","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Sol-Gel Technologies","amount2":0.029999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0.029999999999999999,"dosageForm":"Topical Cream","sponsorNew":"Sol-Gel Technologies \/ M. Arkin Dermatology Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Sol-Gel Technologies \/ M. Arkin Dermatology Ltd"},{"orgOrder":0,"company":"Oneness Biotech","sponsor":"Leo Pharma","pharmaFlowCategory":"D","amount":"$570.0 million","upfrontCash":"$40.0 million","newsHeadline":"LEO Pharma Enters License Agreement with Oneness Biotech and Microbio Shanghai for FB825","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"TAIWAN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"FB825","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Oneness Biotech","amount2":0.56999999999999995,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.56999999999999995,"dosageForm":"Intravenous Infusion","sponsorNew":"Oneness Biotech \/ LEO Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Oneness Biotech \/ LEO Pharma"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Kubota Vision Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Kubota Vision Announces Signing of Open Innovation Agreement with LEO Pharma ","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Discovery","country":"DENMARK","productType":"Undisclosed","productStatus":"Undisclosed","date":"April 2020","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"VAP-1","url1":"","url2":"","graph1":"Dermatology","graph2":"Discovery","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Leo Pharma \/ Kubota Vision Inc","highestDevelopmentStatusID":"2","companyTruncated":"Leo Pharma \/ Kubota Vision Inc"},{"orgOrder":0,"company":"Biofrontera","sponsor":"Maruho Co, Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$6.4 million","newsHeadline":"Biofrontera AG Enters Into Exclusive License Agreement with Maruho Co., Ltd.","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Aminolevulinic Acid HCl","moa":"PPIX","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biofrontera","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Biofrontera \/ Maruho Co, Ltd","highestDevelopmentStatusID":"12","companyTruncated":"Biofrontera \/ Maruho Co, Ltd"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Tetra Receives its 4th FDA Orphan Drug Designation","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Tetrahydrocannabinol","moa":"CB1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Tetra BioPharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Tetra BioPharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Tetra BioPharma \/ Not Applicable"},{"orgOrder":0,"company":"Foamix Pharmaceuticals","sponsor":"Cutia Therapeutics","pharmaFlowCategory":"D","amount":"$11.0 million ","upfrontCash":"$10.0 million","newsHeadline":"Menlo Therapeutics and Cutia Therapeutics ink License Agreement for AMZEEQ\u2122 and Approved Topical Minocycline Products in Greater China","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"April 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Foamix Pharmaceuticals","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.01,"dosageForm":"Topical Foam","sponsorNew":"Foamix Pharmaceuticals \/ Cutia Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Foamix Pharmaceuticals \/ Cutia Therapeutics"},{"orgOrder":0,"company":"CARA Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Another PhIII win in hand, Cara aims straight for priority review of 'breakthrough' pruritus drug","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Difelikefalin","moa":"Kappa opioid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"CARA Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CARA Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CARA Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Arcutis Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arcutis Announces Enrollment of First Patient in Phase 1\/2b Study of ARQ-252 in Patients with Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"ARQ-252","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Arcutis Biotherapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Arcutis Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcutis Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2020","year":"2020","type":"Not Applicable","leadProduct":"Vixarelimab","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Kiniksa Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kiniksa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiniksa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amgen Announces Positive Top-Line Results From Otezla\u00ae (apremilast) Phase 3 ADVANCE Study In Mild-To-Moderate Plaque Psoriasis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Apremilast","moa":"PDE4","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Amgen Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"HPAPI","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lipidor Presents Updated Project Plan - Initiates Phase III study of AKP02 in-House","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Calcipotriol","moa":"Vitamin D3 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Not Applicable"},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Receives US FDA IND Approval to Initiate Phase 1b\/2a Trial of HST 001 in Androgenic Alopecia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"HST 001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Not Applicable"},{"orgOrder":0,"company":"Chelexa Biosciences","sponsor":"Hoth Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Hoth Therapeutics Procures Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatment","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"Antimicrobial therapy","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Chelexa Biosciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Chelexa Biosciences \/ Hoth Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Chelexa Biosciences \/ Hoth Therapeutics"},{"orgOrder":0,"company":"Galderma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Galderma Announces Top-Line Results of Clinical Study Showing Patients Treated with Dysport\u00ae Achieved High Levels of Satisfaction","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"AbobotulinumtoxinA","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase IV","graph3":"Galderma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Galderma \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Galderma \/ Not Applicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alvotech Announces Positive Top-Line Results for Two Comparative Studies for AVT02, a Proposed Biosimilar to HUMIRA\u00ae (Adalimumab)","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alvotech","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Alvotech \/ Not Applicable"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Aleor Dermaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alembic Pharmaceuticals Announces Its Joint Venture, Aleor Dermaceuticals Receives USFDA Approval for Clobetasol Propionate Shampoo, 0.05%","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Clobetasol Propionate","moa":"Glucocorticoid receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Steroid","amount2New":0,"dosageForm":"Shampoo","sponsorNew":"Alembic Pharmaceuticals Limited \/ Aleor Dermaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Alembic Pharmaceuticals Limited \/ Aleor Dermaceuticals"},{"orgOrder":0,"company":"Akari Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Akari Therapeutics Receives Positive EMA Opinion on Orphan Designation for Nomacopan for Bullous Pemphigoid","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Nomacopan","moa":"Completent C5","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Akari Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akari Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akari Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Conatus Pharmaceuticals","sponsor":"Histogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Histogen Announces Successful Completion of its Merger with Conatus Pharmaceuticals","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Merger","leadProduct":"HST 001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Conatus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Conatus Pharmaceuticals \/ Histogen","highestDevelopmentStatusID":"6","companyTruncated":"Conatus Pharmaceuticals \/ Histogen"},{"orgOrder":0,"company":"Dermavant Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dermavant Announces Publication in JAAD of Secondary Efficacy and Patient-Reported Outcomes in Phase 2b Clinical Trial of Tapinarof Cream","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tapinarof","moa":"Aryl hydrocarbon receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Dermavant Sciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Topical","sponsorNew":"Dermavant Sciences \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Dermavant Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Corbus Pharmaceuticals Reports Last Subject Visit in RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Lenabasum","moa":"CB2","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Corbus Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Corbus Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Corbus Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menlo Therapeutics Announces Covered Status for AMZEEQ\u00ae (minocycline) topical foam, 4%, on Additional Commercial Formulary","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Menlo Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Menlo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Menlo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"SPARC","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","amount":"$145.0 million","upfrontCash":"$20.0 million","newsHeadline":"SPARC, Sun Pharma Ink Pact to Develop & Commercialize SCD-044 to Treat Inflammatory Diseases","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"May 2020","year":"2020","type":"Licensing Agreement","leadProduct":"SCD-044","moa":"S1P1 receptor","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"SPARC","amount2":0.14999999999999999,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.14999999999999999,"dosageForm":"Oral","sponsorNew":"SPARC \/ Sun Pharma","highestDevelopmentStatusID":"8","companyTruncated":"SPARC \/ Sun Pharma"},{"orgOrder":0,"company":"Revance Therapeutics","sponsor":"Viatris","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"$25.0 million","newsHeadline":"Revance and Mylan to Advance Development Program for Biosimilar to BOTOX\u00ae","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Undisclosed","country":"","productType":"Large molecule","productStatus":"Biosimilar","date":"June 2020","year":"2020","type":"Licensing Agreement","leadProduct":"OnabotulinumtoxinA","moa":"Ach release","url1":"","url2":"","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Revance Therapeutics","amount2":0.10000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Undisclosed","highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"Intramuscular Injection","sponsorNew":"Revance Therapeutics \/ Mylan","highestDevelopmentStatusID":"1","companyTruncated":"Revance Therapeutics \/ Mylan"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"LEO Pharma Presents Phase 3 Data in Atopic Dermatitis and Plaque Psoriasis at the American Academy of Dermatology Virtual Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Tralokinumab","moa":"IL-13","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Leo Pharma","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Leo Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Leo Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Asana BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Asana BioSciences Announces Topline Results from Phase 2b Study of Oral JAK\/SYK Inhibitor Gusacitinib in Patients with Chronic Hand Eczema","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Gusacitinib","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Asana BioSciences","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Oral","sponsorNew":"Asana BioSciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Asana BioSciences \/ Not Applicable"},{"orgOrder":0,"company":"Menlo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Menlo Therapeutics Announces Positive Results from Phase 2 Trial of FCD105 for the Treatment of Moderate-to-Severe Acne Vulgaris","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Minocycline Hydrochloride","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Menlo Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Foam","sponsorNew":"Menlo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Menlo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Histogen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Histogen Begins Enrollment in Phase 1b\/2a Trial of HST 001 to Treat Androgenic Alopecia","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"HST 001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Histogen","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I\/ Phase II","highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Histogen \/ Not Applicable"},{"orgOrder":0,"company":"Hoth Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoth Therapeutics Provides Shareholder Update on Therapeutics Pipeline","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"VNLG 152","moa":"Retinoic acid metabolism","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Hoth Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Hoth Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hoth Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Complete Results from Second Pivotal Monotherapy Study of Abrocitinib Published in JAMA Dermatology","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Abrocitinib","moa":"JAK1","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"Pfizer Inc","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Pfizer Inc \/ Not Applicable"},{"orgOrder":0,"company":"Follicum AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Follicum Re-Starts phase II Study With FOL-005 for Stimulation of Hair Growth and Expands the Number of Study Centres","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"","productType":"Peptide","productStatus":"New Molecular Entity","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"FOL-005","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Follicum AB","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Follicum AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Follicum AB \/ Not Applicable"},{"orgOrder":0,"company":"Kymera Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4 Role in Hidradenitis Suppurativa and Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"IRAK4","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical","graph3":"Kymera Therapeutics","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kymera Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kymera Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Histogen","sponsor":"Conatus Pharmaceuticals","pharmaFlowCategory":"D","amount":"$135.1 million","upfrontCash":"Undisclosed","newsHeadline":"Conatus Pharmaceuticals and Histogen Enter into Definitive Merger Agreement","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","year":"2020","type":"Merger","leadProduct":"HST 001","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Histogen","amount2":0.14000000000000001,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0.14000000000000001,"dosageForm":"Intradermal Injection","sponsorNew":"Histogen \/ Conatus Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Histogen \/ Conatus Pharmaceuticals"},{"orgOrder":0,"company":"TWi Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TWiB Receives Canada Health Approval for AC-1101 Phase 1 CTA","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Tofacitinib Citrate","moa":"JAK","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase I","graph3":"TWi Biotechnology","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","productSubType":"","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"TWi Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"TWi Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Follica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Follica Announces Positive Feedback From End of Phase 2 Meeting With FDA for Its Lead Program to Treat Mal
Market Place